Skip to main content
. Author manuscript; available in PMC: 2013 Sep 15.
Published in final edited form as: Int J Pharm. 2012 May 23;434(1-2):306–314. doi: 10.1016/j.ijpharm.2012.05.028

Fig.6A.

Fig.6A

Vandetanib plasma concentration-time profile in the absence and presence of specific P-gp (LY335979, 25mg/kg), Bcrp1 (Ko143, 10mg/kg) and dual P-gp/Bcrp1 inhibitor (GF120918, 10mg/kg) administered i.v, 30 min prior to a single intravenous dose of vandetanib (5mg/kg) through tail vein in FVB-wild type mice. Results are expressed as Mean±S.E., n=3.